| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $2.5M | +5.6% | -54.1% |
| SG&A Expense | $2.3M | -36.2% | -70.3% |
| Operating Income | -$4.9M | +19.7% | +63.6% |
| Net Income | -$4.4M | +18.4% | +69.7% |
| EPS (Basic) | -$1.41 | +58.4% | -281.1% |
| EPS (Diluted) | -$1.41 | +58.4% | -252.5% |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $12.6M | +13.7% | -63.4% |
| Current Assets | $13.6M | +8.0% | -62.1% |
| Total Assets | $14.6M | +6.8% | -60.8% |
| Current Liabilities | $4.9M | -16.3% | -75.8% |
| Total Liabilities | $5.2M | -15.7% | -74.7% |
| Stockholders' Equity |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$18.8M | — | — |
| Capital Expenditures | $43K | — | — |
| Investing Cash Flow | -$43K | — | — |
| Financing Cash Flow | $8.0M | — | — |
| Free Cash Flow | -$18.8M | — | — |
| $8.0M |
| +31.4% |
| -47.3% |